Knockdown of NEK6 restores the sensitivity of CRPC cells to ADT in PCa xenograft models [76], suggesting that combined NEK6 inhibition with ADT would be an effective therapeutic strategy for CRPC. The gene discussed is NEK6; the disease is posterior cortical atrophy.